RCMNY
KNSA icon

Rubric Capital Management (New York)’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Rubric Capital Management (New York)’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$256M Buy
3,999,800
+249,800
+7% +$13M 2.35% 9
2026
Q1 		$181M Buy
3,750,000
+421,347
+13% +$18.7M 1.91% 13
2025
Q4 		$137M Sell
3,328,653
-671,347
-17% -$26.9M 1.64% 16
2025
Q3 		$155M Buy
4,000,000
+90,194
+2% +$2.93M 1.75% 13
2025
Q2 		$108M Buy
3,909,806
+526,567
+16% +$13.4M 1.63% 16
2025
Q1 		$75.1M Buy
3,383,239
+764,136
+29% +$15.7M 1.35% 22
2024
Q4 		$51.8M Buy
2,619,103
+200,000
+8% +$4.56M 0.66% 31
2024
Q3 		$60.5M Hold
2,419,103
– – 0.99% 26
2024
Q2 		$45.2M Buy
2,419,103
+223,094
+10% +$4.18M 1.18% 35
2024
Q1 		$43.3M Sell
2,196,009
-711,492
-24% -$13.9M 1.28% 29
2023
Q4 		$51M Sell
2,907,501
-169,948
-6% -$2.79M 1.06% 22
2023
Q3 		$53.5M Sell
3,077,449
-300,715
-9% -$5.07M 2.01% 16
2023
Q2 		$47.6M Buy
3,378,164
+602,528
+22% +$8.06M 2.03% 20
2023
Q1 		$29.9M Buy
2,775,636
+1,206,133
+77% +$15.9M 0.77% 32
2022
Q4 		$23.5M Buy
1,569,503
+123,396
+9% +$1.8M 1.03% 34
2022
Q3 		$18.6M Buy
1,446,107
+922,579
+176% +$10.5M 0.94% 35
2022
Q2 		$5.07M Buy
+523,528
New +$4.88M 0.27% 60
2021
Q4 		– Sell
-153,618
Closed -$1.75M – 76
2021
Q3 		$1.75M Buy
+153,618
New +$2M 0.05% 57

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Rubric Capital Management (New York)'s KNSA Position: Q2 2026 in Review

Rubric Capital Management (New York) increased its Kiniksa Pharmaceuticals (KNSA) stake by 6.7% in Q2 2026, buying an estimated $13M and bringing the position to 3,999,800 shares worth $256M. The position accounts for 2.35% of the portfolio, ranked #9.

Rubric Capital Management (New York) first reported a position in KNSA in Q3 2021 and has held it in 18 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Rubric Capital Management (New York) held 3,999,800 shares of Kiniksa Pharmaceuticals worth $256M as of Q2 2026.
  • Rubric Capital Management (New York) bought 249,800 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $13M.
  • Kiniksa Pharmaceuticals made up 2.35% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #9 holding.
  • Rubric Capital Management (New York) first reported a position in Kiniksa Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.